DIMERIX LIMITED — Capital/Financing Update 2014

Sep 17, 2014

Limited

18 September 2014

Company Announcements Office ASX Limited Level 4, Exchange Centre 20 Bridge Street SYDNEY NSW 2000

INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

Further to the Appendix 3B lodged on 18 September 2014 for the issue of 82,500,000 fully paid ordinary shares ( Placement ), Sun Biomedical Limited (ASX: SBN) provides the following information required under ASX Listing Rule 3.10.5A:

• (a) The dilutive effect of the Placement on existing shareholders is as follows:

Number of Shares on issue prior to the Placement: 331,140,008

r to the Appendix 3B lodged on 18 September 2014 for the issue of 82,500,00ry shares (Placement), Sun Biomedical Limited (ASX: SBN) provides theation required under ASX Listing Rule 3.10.5A:The dilutive effect of the Placement on existing shareholders is as follows:Number of Shares on issue prior to the Placement: 331,140,008	0 fully paidfollowing
Placement issue under ListingRule 7.1 (49,671,001 shares)	15.00%
Placement issue under ListingRule 7.1A (32,828,999 shares)	9.91%
Total dilution as a result of the Placement	24.91%

Number of Shares on issue following the Placement: 413,640,008

Details of the approximate percentage of the issued capital following the completion of the Placement held by pre-Placement shareholders and new shareholders are as follows. Please note this information relates specifically in relation to the portion of shares issued under Listing Rule 7.1A (32,828,999 shares):

Rule 7.1A (32,828,999 shares):
Pre-Placement shareholders who did notparticipate in the Placement	100%
Pre-Placement shareholders who didparticipate in the Placement	-
Participants in the Placement who werepreviouslynot shareholders	100%

• (b) The Company issued the shares as a placement under Listing Rule 7.1A as it believed that this was the most efficient mechanism for raising funds at the time. The Company had also received an expression of interest from a broker to support the placement making it a more reliable process to fund.

• (c) No underwriting arrangements were in place for the Placement; and

• (d) A fee of 6% totalling $60,000 (before GST) will be paid to Forrest Capital Pty Ltd for the amount raised in relation to the Placement.

Yours faithfully

==> picture [78 x 55] intentionally omitted <==

Peter Webse Company Secretary

Sun Biomedical Limited ABN 18 001 285 230

Level 2, 1 Walker Avenue, West Perth WA 6005

ASX: SBN

www.sunbiomed.com.au

T: +61 8 9481 3860 | F: +61 8 9321 1204